Acadia Faces EMA Setback On Rett Drug As Regulatory Test Looms [Yahoo! Finance]
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Yahoo! Finance
Acadia Pharmaceuticals (NasdaqGS:ACAD) received a negative trend vote from the European Medicines Agency's Committee for Medicinal Products for Human Use on its Rett syndrome treatment, trofinetide. The company plans to seek a re examination of the opinion as part of the ongoing regulatory review process in Europe. Trofinetide is a key part of Acadia's rare disease portfolio, so this regulatory signal from the EMA is an important event for anyone following NasdaqGS:ACAD. The focus now turns to how the re examination request progresses and what additional information regulators may look for around the Rett syndrome data package. For investors, this sits alongside broader interest in approved and pipeline products in central nervous system and rare disease treatment. From here, attention will likely center on the timing and outcome of the EMA re examination, as well as any updates Acadia provides on its engagement with European regulators. Readers may also watch for how the compa
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $21.00 to $23.00. They now have a "market perform" rating on the stock.MarketBeat
- ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "market perform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..MarketBeat
- Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026Business Wire
- Exploring US High Growth Tech Stocks This February 2026 [Yahoo! Finance]Yahoo! Finance
ACAD
Earnings
- 11/5/25 - Beat
ACAD
Sec Filings
- 2/10/26 - Form 4
- 1/13/26 - Form 8-K
- 11/19/25 - Form 4
- ACAD's page on the SEC website